Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA 1345

Next Previous
Drug Profile

mRNA 1345

Alternative Names: mRESVIA; mRNA-1345; Respiratory syncytial virus vaccine - Moderna Therapeutics

Latest Information Update: 19 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Class RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Respiratory syncytial virus infections
  • Phase I Metapneumovirus infections

Most Recent Events

  • 12 Jun 2025 FDA approves mRNA-1345 for Respiratory syncytial virus infections (In adults, Monotherapy, Prevention) in USA
  • 12 Jun 2025 Moderna Therapeutics announces intention to launch mRESVIA for Respiratory syncytial virus infections (In adults, In the elderly, Prevention) for the 2025-2026 respiratory virus season in the US
  • 12 Jun 2025 Adverse events and immunogenicity data from a phase-III trial in Respiratory syncytial virus infections (In adults, Monotherapy, Prevention) released by Moderna Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top